GSK plc is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK&rsquo...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered porta...
Certara, Inc. a global leader in model-informed drug development, announced the launch of its Non-Animal Navigator™ solution designed to help bi...
Celltrion, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated YUFLYMA® (adalimumab-aaty), as an interchangeable biosim...
INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment t...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that results from a Phase 3 registrational clinical study evaluating...
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThe...
Amgen, announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...
Vantage Biosciences is a clinical-stage biotechnology company developing innovative therapies for the treatment of diabetic eye diseases. The company ...
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food a...
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a collaboration with the National Cancer Institu...
Odylia Therapeutics (Odylia) a nonprofit biotechnology company dedicated to expediting drug development for rare diseases, hosted a Rare Disease Day event ...
AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy®...
© 2025 Biopharma Boardroom. All Rights Reserved.
